Miares: Virginia to receive $ 530 million to fight opioid crisis

RICHMAND, Virginia (WRIC) – Attorney General Jason Miares has announced the final approval of a $ 26 billion opioid deal between Cardinal, McKeson and Amerisource Bergen of Johnson & Johnson. The Commonwealth expects to receive $ 530 million to combat the opioid crisis.

According to the Prosecutor General’s Office, after successful periods of registration and registration of units, the accused will begin to issue funds to the national administrator on April 2, 2022. The money will go to state and local authorities in the second quarter of 2022.

“The opioid crisis has devastated many communities, families and lives in Virginia. The Attorney General is dedicated to this struggle and is proud to have played a role in this historic settlement, which has been joined by every city and county in Virginia. As a result, the Commonwealth expects to receive approximately $ 530 million to fight the opioid epidemic and support efforts to reduce, prevent and treat opioid dependence, ”said Attorney General Miares.

Fifty-two states and territories have signed the agreement, as well as thousands of local governments across the country. In Virginia, all 95 counties and all 38 independent cities have signed the agreement.

According to the release, Virginia expects to receive approximately $ 530 million. Funding helps support efforts to reduce, prevent and treat opioid-related disorders, as well as combat the opioid epidemic.

According to the release – in addition to funds, Cardinal, McKesson and AmerisourceBergen will:

  • Establish a centralized independent clearing to provide all three distributors and government regulators with summary data and analysis of where and how often drugs fall, eliminating blind spots in current systems used by distributors.
  • Use data-driven systems to detect suspicious opioid orders from customer pharmacies.
  • Stop the ability of pharmacy customers to receive supplies and report these companies to government regulators if they show certain signs of redirection.
  • Prohibit delivery and report suspicious opioid orders.
  • Prohibit sales staff from influencing decisions related to the detection of suspicious opioid orders.
  • Require senior corporate officials to participate in regular oversight of anti-sabotage efforts.

Johnson & Johnson must:

  • Stop selling opioids.
  • Do not fund or provide grants to third parties to promote opioids.
  • Do not lobby for opioid-related activities.
  • Share clinical research data from Yale University’s Open Data Access Project.

Source link

USA News